FOR A METASTATIC NSCLC PATIENT

HE HAS

ONE CHANCE

AT FIRST-LINE THERAPY

Knowing his mutation status may mean the difference between getting the right first-line treatment or not

ARE YOU SURE YOU MADE THE RIGHT CHOICE?

TEST EVERY mNSCLC PATIENT

In metastatic NSCLC

ONE MISSED PATIENT
IS ONE TOO MANY

BE SURE your patients get all the molecular testing they need

 

1 IN 3 patients with lung adenocarcinoma has an actionable mutation1-3

 

BE SURE to test all mNSCLC patients for oncogenic mutations, regardless of phenotype

  • National Comprehensive Cancer Network® (NCCN®) recommends clinicopathologic features such as ethnicity, smoking status, or histology NOT be used to select patients for EGFR mutational testing4

BE SURE. Don’t settle for an unknown molecular status

  • NCCN recommends that repeat biopsy and/or plasma testing should be done if initial biopsy is insufficient if feasible4

BE SURE to test all mNSCLC patients for oncogenic mutations, regardless of phenotype

  • National Comprehensive Cancer Network® (NCCN®) recommends clinicopathologic features such as ethnicity, smoking status, or histology NOT be used to select patients for EGFR mutational testing4

BE SURE. Don’t settle for an unknown molecular status

  • NCCN recommends that repeat biopsy and/or plasma testing should be done if initial biopsy is insufficient if feasible4
To be sure of your first-line treatment choice is to know their full molecular profile
KNOW THEIR FULL RESULTS

In metastatic NSCLC

INTEGRATE LIQUID BIOPSY

TO BE SURE OF THEIR STATUS

Optimal treatment starts with knowing the driver of their disease

ARE YOU USING BOTH TISSUE AND LIQUID BIOPSY?

INTEGRATE LIQUID BIOPSY

In metastatic NSCLC

LIQUID BIOPSY PLUS TISSUE TESTING ARE CRITICAL IN HELPING TO FIND MORE ACTIONABLE MUTATIONS

LIQUID BIOPSY CAN HELP YOU BE SURE OF YOUR PATIENT’S STATUS

QNS
In cases of QNS (quantity not sufficient)
In patients with tissue QNS, ~28% were found to have actionable mutations with liquid biopsy
QNS
When tissue is not feasible
In patients who were unable to have a tissue biopsy, ~23% were found to have actionable mutations with liquid biopsy
QNS
When fast turnaround time is critical
Liquid biopsy results were received within a median of 9 days, according to a clinical study6||
  

Use both liquid biopsy and tissue to help make a difference for every mNSCLC patient identified

  • Liquid biopsy and tissue together increased detection of actionable mutations by 17% over mutations found in tissue alone5
*
Based on 3 studies of patients with adenocarcinoma; Sholl et al, 2015, included 733 patients with lung adenocarcinoma but did not test patients for ROS1 rearrangements or NTRK fusions.1-3
Percentage adjusted based on aggregate of Sholl et al, Stransky et al, and Bergethon et al.
If plasma test is negative, consider reflexing to tissue testing.7
§
Single-center prospective US study of 323 patients with stage IV NSCLC using next-generation sequencing as the testing platform.5
||
Multicenter US study of 307 patients with stage IIIB or IV NSCLC using next-generation sequencing as the testing platform.6

References: 1. Sholl LM, Aisner DL, Varella-Garcia M, et al; LCMC Investigators. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium experience. J Thorac Oncol. 2015;10(5):768-777. 2. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun. 2014;5:4846. doi:10.1038/ncomms5846. 3. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863-870. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC V.3.2020. ©National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed February 11, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180. 6. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700. 7. Merker JD, Oxnard GR, Compton C, et al. Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review. J Clin Oncol. 2018;36(16):1631-1641.

COVID-19 RESOURCES

COVID-19 Resources and Information

AstraZeneca is committed to providing resources for cancer patients, their loved ones, and healthcare professionals during these uncertain times. Here are public health organizations and institutions offering general guidance for cancer patients and their caregivers.

Lung Cancer and COVID-19

Resources from GO2 Foundation for Lung Cancer

Resources from LUNGevity

 

Loading......